Secondary prevention in patients with coronary artery disease in Russia and Europe: results from the Russian part of the EUROASPIRE V survey

Aim. To assess the secondary prevention in Russian patients with coronary artery disease in the long-term period after acute myocardial infarction, acute coronary syndrome (ACS), percutaneous coronary intervention and/or coronary artery bypass grafting, obtained in the European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE V) survey in comparison with the general population of the study.

Material and methods. EUROASPIRE V is a cross-sectional study with 27 countries, including Russia, which involved patients with ACS or indications for myocardial revascularization. At participating centers, patients admitted to hospital due to ACS or for percutaneous coronary intervention or coronary artery bypass grafting were identified. After 6 months and <2 years after discharge, patients were examined.

Results. In total, 699 patients were identified in Russia, 399 of which visit an interview (women, 27,1%; mean age, 62,8±8,7 years). In the general population of the study, 16,208 patients were identified, 8,261 of which were interviewed (women, 25,8%; mean age, 63,6±9.6 years). At the time of the interview, 18,5% of Russian patients continued to smoke (16,8% in the general study population), the prevalence of overweight or obesity – 85,4 and 81,7%, abdominal obesity – 60,4 and 58,5%, diabetes – 21,9 and 29,3% of patients, respectively. In 19,7 and 16,4% of patients, respectively, diabetes was first diagnosed with a glucose tolerance test in the study. The target glycated hemoglobin was achieved in 47,1 and 54,4%, blood pressure – in 64,0 and 53,7%, low-density lipoprotein cholesterol – in 27,6 and 29,0% of patients, respectively.

Conclusion. There were significant differences between the Russian cohort and the general study population. Some key secondary prevention parameters were more favorable in the Russian cohort, and some parameters – in the general group. In both compared populations, significant reserves are retained for further optimization.

coronary artery disease, secondary prevention, risk factors, target levels

1. Timmis A, Townsend N, Gale CP, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J. 2020;41(1):12-85. doi:10.1093/eurheartj/ehz859.

2. Piepoli MF, Abreu A, Albus C, et al. Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. Eur J Prev Cardiol. 2020;27(2):181-205. doi:10.1177/2047487319893035.

3. Pogosova NV, Oganov RG, Suvorov SV. Why cardiovascular mortality in Moscow is lower than regions of the Russian Federation? Cardiovascular Therapy and Prevention 2015;14(2):4-12. (In Russ.) Погосова Н.В., Оганов Р.Г., Суворов С.В. Почему в Москве смертность от сердечно-сосудистых заболеваний ниже, чем в других регионах Российской Федерации? Кардиоваскулярная терапия и профилактика. 2015;14(2):4-12. doi:10.15829/1728-8800-2015-2-4-12.

4. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J. 1997;18:1569-82. doi:10.1093/oxfordjournals.eurheartj.a015136.

5. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J. 2001;22:554-72. doi:10.1053/euhj.2001.2610.

6. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from twenty-two European countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121-37. doi:10.1097/HJR.0b013e3283294b1d.

7. Kotseva K, Wood D, De Bacquer D, et al. on behalf of the EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. European Journal of Preventive Cardiology. 2016 Apr;23(6):636-48. doi:10.1177/2047487315569401.

8. Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824-35. doi:10.1177/2047487318825350.

9. Pogosova N, Oganov R, Saner H, et al. Potential and limitations of health policy to improve coronary heart disease prevention and to reduce the burden of disease: A Russian experience. Eur J Prev Cardiol. 2018;25(16):1725-34. doi:10.1177/2047487318768030.

10. Pogosova N, Sokolova O. Governmental efforts for cardiovascular disease prevention efforts in the Russian Federation. Cardiovasc Diagn Ther. 2017;7(Suppl 1):S48-54. doi:10.21037/cdt.2017.03.01.

11. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81. doi:10.1093/eurheartj/ehw106.

12. Pogosova GV, Oganov RG, Koltunov IE, et al. Monitoring of Secondary Prevention of Ischemic Heart Disease in Russia and European Countries: Results of International Multicenter Study EUROASPIRE III. Kardiologiia. 2011;1:34-40. (In Russ.)

13. Pogosova NV, Oganov RG, Boytsov SA, et al. Psychosocial factors and life quality in coronary heart disease patients: results of the Russian part of international multicenter study EUROASPIRE IV. Cardiovascular Therapy and Prevention. 2017;16(5):20-6. (In Russ.) doi:10.15829/1728-8800-2017-5-20-26.

14. Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010;121:750-8. doi:10.1161/CIRCULATIONAHA.109.891523.

15. Biery DW, Berman AN, Singh A, et al. Association of Smoking Cessation and Survival Among Young Adults With Myocardial Infarction in the Partners YOUNG-MI Registry. JAMA Netw Open. 2020;3(7):e209649. doi:10.1001/jamanetworkopen.2020.9649.

16. Wilkins E, Wilson L, Wickramasinghe K, et al. (2017) European Cardiovascular Disease Statistics 2017. European Heart Network, Brussels. http://www.ehnheart.org/images/CVD-statistics-report-August-2017.pdf (16 November 2020).

17. Sahakyan KR, Somers VK, Rodriguez-Escudero JP, et al. Normal-Weight Central Obesity: Implications for Total and Cardiovascular Mortality. Ann Intern Med. 2015;163(11):827-35. doi:10.7326/M14-2525.

18. Primack C. A review and critique of published real-world weight management program studies. Postgrad Med. 2018;130(6):548-60. doi:10.1080/00325481.2018.1498280.

19. Fildes A, Charlton J, Rudisill C, et al. Probability of an Obese Person Attaining Normal Body Weight: Cohort Study Using Electronic Health Records. Am J Public Health. 2015;105(9):e54-9. doi:10.2105/AJPH.2015.302773.

20. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486.

21. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2020. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf (16 November 2020).